E Fund Management Co. Ltd. Sells 2,472 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

E Fund Management Co. Ltd. lowered its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 9.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,695 shares of the biopharmaceutical company’s stock after selling 2,472 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Amicus Therapeutics were worth $223,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Los Angeles Capital Management LLC increased its holdings in shares of Amicus Therapeutics by 46.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 20,474 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 6,484 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in Amicus Therapeutics by 163.8% during the 3rd quarter. GSA Capital Partners LLP now owns 133,800 shares of the biopharmaceutical company’s stock valued at $1,429,000 after purchasing an additional 83,081 shares during the last quarter. OLD Second National Bank of Aurora bought a new position in Amicus Therapeutics during the third quarter worth $26,000. Tokio Marine Asset Management Co. Ltd. bought a new position in shares of Amicus Therapeutics in the third quarter valued at about $113,000. Finally, Wrapmanager Inc. bought a new position in shares of Amicus Therapeutics in the third quarter valued at about $220,000.

Amicus Therapeutics Trading Down 1.8 %

FOLD opened at $8.86 on Monday. The stock has a market capitalization of $2.72 billion, a price-to-earnings ratio of -49.22, a P/E/G ratio of 1.51 and a beta of 0.69. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a twelve month low of $8.78 and a twelve month high of $12.65. The company has a 50-day simple moving average of $9.43 and a 200 day simple moving average of $10.24.

Analyst Ratings Changes

FOLD has been the topic of several research analyst reports. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. JPMorgan Chase & Co. increased their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Finally, Wells Fargo & Company reduced their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.